DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Hermansky-Pudlak syndrome 8 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHermansky-Pudlak syndrome 8 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hermansky-pudlak syndrome 8 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
microtubule affinity regulating kinase 4 (MARK4) — MARK4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1~{r},6~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5ES1 · 2.8 Å · ligand ~{N}-[(1~{R},6~{R})-6-azanyl-2,2-bis(fluoranyl)cyclohexyl]-5-ethyl-4-[6-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]thiophene-2-carboxamide (5RC). Experimental structure, not a prediction.
What the evidence adds up to
Hermansky-Pudlak syndrome is a rare autosomal recessive disorder with nine known subtypes. It is characterised by oculocutaneous albinism, a platelet storage pool deficiency causing a bleeding diathesis, and lysosomal accumulation of ceroid lipofuscin. Patients with genotypes HPS-1, HPS-2, or HPS-4 are predisposed to interstitial lung disease, and some develop granulomatous colitis. The syndrome has been described globally but has its highest frequency in a cluster population in Puerto Rico. Rarely, cardiomyopathy and renal dysfunction have been described. The cellular machinery involved in HPS is thought to be ancient, based on identification of conserved protein families including human HPS4.
A 2020 study used next-generation sequencing panel analysis covering all ten HPS genes to diagnose three patients presenting with oculocutaneous albinism, nystagmus, and increased bleeding tendency. Platelet aggregometry and flow cytometry confirmed pathological platelet function and decreased platelet delta granule secretion. Two brothers shared a compound heterozygous genotype consisting of a novel splice variant (c.987+1[G>A]) and a previously reported mutation (c.1189[delC]) in the HPS1 gene. An unrelated third patient had the same c.1189[delC] deletion compound heterozygous with another reported deletion (c.355[delC]). The authors concluded that early genetic diagnosis of the HPS type is important because HPS1 patients are at risk of developing pulmonary fibrosis at middle age.
A 2005 report described a case of the oldest historical patient with HPS type 6 and discussed gastrointestinal management. A 2021 paper noted that the bleeding diathesis in HPS presents a challenge for clinicians, particularly during procedures such as cardiac catheterisation. Common manifestations across subtypes include nystagmus, lighter skin and hair colour than family members, prolonged bleeding after minor procedures, pulmonary fibrosis, colitis, and neutropenia.
No drug treatment is tested or recommended in any of these abstracts. What is missing is any clinical trial data for pharmacological intervention in any HPS subtype, including HPS-8 specifically. There is no evidence on patient stratification beyond genotype, no funded trial design for repurposing candidates, and no survival or response rate data for any therapy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PEDIATRICS · 2013 · 126 citations
Hermansky-Pudlak Syndrome: Health Care Throughout Life
AbstractHermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disease that displays genetic heterogeneity; there are 9 known subtypes. HPS is characterized by oculocutaneous albinism, a platelet storage pool deficiency and resultant bleeding diathesis, and lysosomal accumulation of ceroid lipofuscin. Patients with HPS, specifically those with the genotypes HPS-1, HPS-2, or HPS-4, are predisposed to interstitial lung disease. In addition, some patients with HPS develop granulomatous colitis. Optimal health care requires a thorough knowledge of the unique health risks and functional limitations associated with this syndrome.
Journal of Clinical Gastroenterology · 2010 · 37 citations
The Management of Gastrointestinal Disease in Hermansky-Pudlak Syndrome
AbstractHermansky-Pudlak syndrome (HPS) was first described in 1959 by Hermansky and Pudlak. Clinically, HPS is characterized by oculocutaneous albinism, platelet storage pool deficiency, and ceroid tissue accumulation. It is a rare disorder that has been described globally but has the highest frequency in a cluster population in Puerto Rico. HPS patients also have major organ involvement that typically includes pulmonary fibrosis and granulomatous colitis. Rarely have cardiomyopathy and renal dysfunction been described. We report a case of the oldest historical patient with HPS type 6 and the associated gastrointestinal management.
The CHiPS Domain – Ancient Traces for the Hermansky–Pudlak Syndrome
AbstractHermansky-Pudlak syndrome (HPS) is a rare disorder caused by malfunctions of lysosomes and specialized lysosome-related organelles, resulting primarily in oculocutaneous albinism and bleeding diathesis. The majority of the HPS genes have been described as novel, but herein we report the identification of a conserved protein family which includes human HPS4, as well as distant homologs for other HPS genes. Our results suggest that the cellular machinery involved in the HPS syndrome is ancient.
Journal of Case Reports and Images in Medicine · 2021 · 0 citations · open access
Hermansky-Pudlak syndrome subtype 5 (HPS-5): Safety of cardiac catheterization in patients with a bleeding diathesis
AbstractIntroduction: Hermansky-Pudlak syndrome is a rare autosomal recessive form of albinism that leads to defective platelet aggregation and bleeding diathesis. This presents a potential challenge to clinicians involved in the care of these patients. Common manifestations include nystagmus, lighter skin, and hair color than family members, prolonged bleeding after minor procedures, pulmonary fibrosis, colitis, and neutropenia.
Archives of Clinical and Medical Case Reports · 2020 · 0 citations · open access
Panel Sequencing Identified a Novel Splice Site Mutation in Hermansky-Pudlak Syndrome Type 1 Patients
AbstractIntroduction: Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder. Patients with HPS characteristically present with oculocutaneous albinism, nystagmus and increased bleeding tendency. The symptoms are caused by malfunction of lysosome related organelles (i.e. melanosomes, platelets). Patients with HPS typically show impaired platelet delta granule secretion. We report three patients (two brothers and another unrelated patient) who presented with these typical symptoms. Methods and Results: Platelet aggregometry and flow cytometry analyses revealed pathological platelet function and decreased platelet delta granule secretion. Using NGS panel analysis comprising all 10 HPS genes a defect in the HPS1 gene was identified. The brothers share compound heterozygous a novel splice variant (c.987+1[G>A]) and an already reported mutation (c.1189[delC]). Although the third patient is not related with the brothers, he presented with the same one base pair deletion c.1189[delC] compound heterozygous with another already reported base pair deletion (c.355[delC]). Conclusions: Since HPS1 patients are at risk to develop pulmonary fibrosis at middle age, early genetic diagnosis of the HPS type is important for prognosis and treatment. In this study we identified a novel splice site variant (c.987+1[G>A]) in the HPS1 gene, diagnosed the patients as HPS1 type and therefore, enabled adequate follow-up and therapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
